• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Primatene Mist Inhaler rejected by FDA

December 30, 2016 By Sarah Faulkner

FDA rejects Amphastar's Primatene Mist asthma inhalerAmphastar Pharmaceuticals (NSDQ:AMPH) said this week that the FDA denied its subsidiary’s new drug application for the latest version of its Primatene Mist epinephrine inhaler.

The complete response letter from the federal watchdog told Amphastar’s subsidiary, Armstrong Pharmaceuticals, that the company needs to change the inhaler’s label and packaging. The FDA also recommended that the company conduct another human factor validation study to evaluate consumers’ ability to use the product without the help of a healthcare professional.

The company’s next-generation Primatene Mist asthma inhaler contains epinephrine as the active ingredient, just like the original Primatene Mist inhaler. The new version of the device does not include chlorofluorocarbons in the delivery system, since CFCs were phased out of products as a result of a global environmental treaty.

The new Primatene Mist inhaler also features a built-in spray indicator and a pressurized metal canister to replace the glass container in the original device.

“While we are disappointed to have not received approval at this time, we intend to continue to work with the FDA during the post-action phase to address their concerns in the CRL by the middle of 2017 and bring Primatene Mist back to the OTC market as soon as possible,” Amphastar CEO Jack Zhang said in prepared remarks.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Respiratory, Wall Street Beat Tagged With: Amphastar Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Reader Interactions

Comments

  1. Tony says

    October 4, 2017 at 8:34 am

    Are the inhalers available through foreign pharmacies? If so, can you specify?

  2. Jahk says

    March 16, 2018 at 12:59 am

    For fifty years Primatene Mist has helped millions, Now with a new propellant, the FDA denies it? Something smells foul with their decision.

  3. MIke says

    March 19, 2018 at 9:25 am

    Every day I see commercials for new drugs APPROVED by the FDA and 75 percent of the commercial is reserved for the side affects!!! Primatene Mist worked and the government pulled it from the market. So now the only way to get help with asthma is with a prescription. Is there anyone out there who does not believe big Pharma controls the government?

  4. MO says

    October 21, 2018 at 9:55 pm

    Primitene mist was banned because it worked. Now all we can do is get one bottle a month for 50 bucks of cheap albuterol and it half works. This was all about money and has nothing to do with the environment.

  5. Richard says

    November 12, 2018 at 6:31 pm

    The pharmaceutical manufacturers are a bunch of greedy bastards. They just do not take the public into consideration with development and pricing of medications. The gov’t should introduce a plan of cost plus with a 10% profit margin to make it fair to manufacturers and less costly to the public. The gov’t should give them inducements for R. & D. So that it encourages companies to develop meds for diseases that do not affect the public in large numbers. baltman70@aol.com. Thank you.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS